Thus, targeting the CD73/CCL5 axis may prove to be a promising strategy for enhancing immunotherapy efficacy in pancreatic cancer marked by hypoxia-induced immunosuppression. The gene discussed is CCL5; the disease is familial pancreatic carcinoma.